USO 26064

A Global, Interventional, Open-label Trial of T-DXd-based Therapy Followed by Palbociclib, Endocrine Therapy and Dual HER2 Blockade in First-line HER2+/HR+ Advanced or Metastatic Breast Cancer and Retreatment with T-DXd(DESTINY-Breast Guide) Protocol: DS8201-0004-CIS-MA

Disease Types: Breast Cancer Research

Eligibility Requirements:

• Histologically confirmed HR+ and HER2+ la/MBC (local testing)
• No prior chemotherapy or HER2-targeted tx for MBC
• If treated in (neo)adjuvant setting, pt are eligible if DFI >6 months from
completion of systemic tx to PD
• Previous T-DXd tx for eBC with an EFS or DFI of <12 months from
completion of T-DXd tx in the neoadjuvant or post-neoadjuvant setting
are excluded
• 1 prior line of ET tx for MBC is allowed
• Prior tx with any CDK inhibitor are excluded
• > 1 measurable lesion or non-measurable bone-only disease or lytic/mixed
lytic bone lesions assessable by CT, MRI, or X-ray
• Asymptomatic brain metastases (<2 cm) or treated metastases that are no
long symptomatic and requires no treatment are eligible
• Adequate treatment washout period before enrollment (check full protocol
for details.

For more information on this trial CLICK HERE .

Available at:

• Chesapeake
• Newport News (Port Warwick III)
• Norfolk (Brock Cancer Center)
• Virginia Beach (Princess Anne)
• Williamsburg